PEDIATRICS Vol. 97 No. 6 June 1996, pp. 917-920
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Song, J. Y.
Right arrow Articles by Yoon, Y. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Song, J. Y.
Right arrow Articles by Yoon, Y. S.

Long-term Aspirin Therapy for Hepatopulmonary Syndrome

Jin Young Song MD1, Jung Yun Choi MD1, Jun Tae Ko MD2, Eun Jung Bae MD2, Ho Sung Kim MD2, Chung Il Noh MD2, and Yong Soo Yoon MD2

1 Department of Pediatrics, Seoul National University Children's Hospital, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea
2 Department of Pediatrics Seoul National University Children's Hospital, Seoul 110-744, Korea

It is well known that arterial hypoxia can occur with chronic liver disease in adults as well as children.1-3 The clinical syndrome of hypoxia in association with liver disease has been called hepatopulmonary syndrome (HPS) or intrapulmonary vasodilative disease.3,4 In its classic form, HPS is a triad of abnormal arterial oxygenation, hepatic dysfunction, and pulmonary vascular dilation. The primary underlying disease of the hepatobiliary system is mainly liver cirrhosis or other chronic liver disease.4,5 The hypoxia is caused by either right-to-left shunting through arteriovenous connections within the lungs or a ventilation-perfusion imbalance caused by diffuse vasodilation of pulmonary arteries at the precapillary and capillary levels.1-3

Submitted on June 27, 1995
Accepted on February 22, 1996




This article has been cited by other articles:


Home page
 Arch Intern MedHome page
L. B. Gupta, A. Kumar, A. K. Jaiswal, J. Yusuf, V. Mehta, S. Tyagi, D. K. Tempe, B. C. Sharma, and S. K. Sarin
Pentoxifylline Therapy for Hepatopulmonary Syndrome: A Pilot Study
Arch Intern Med, September 8, 2008; 168(16): 1820 - 1823.
[Full Text] [PDF]

Home page
 PediatricsHome page
K. Noli, M. Solomon, F. Golding, M. Charron, and S. C. Ling
Prevalence of Hepatopulmonary Syndrome in Children
Pediatrics, March 1, 2008; 121(3): e522 - e527.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic
Pulmonary-Hepatic vascular Disorders (PHD)
Eur. Respir. J., November 1, 2004; 24(5): 861 - 880.
[Full Text] [PDF]